75567-37-2 | Ingenol Mebutate

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥95%	in stock	$196.00	$137.00
5mg	≥95%	in stock	$711.00	$498.00
10mg	≥95%	in stock	$1,016.00	$711.00

Description

• Catalog Number: AH51074
• Chemical Name: Ingenol Mebutate
• CAS Number: 75567-37-2
• Molecular Formula: C25H34O6
• Molecular Weight: 430.5339
• MDL Number: MFCD07784504
• SMILES: C/C=C(\C(=O)O[C@H]1C(=C[C@]23[C@]1(O)[C@H](O)C(=C[C@H](C3=O)[C@H]1[C@@H](C[C@H]2C)C1(C)C)CO)C)/C

Computed Properties

• Complexity: 926
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 8
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 4
• XLogP3: 2

Literature

• Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens.

  Current opinion in ophthalmology 20120901

• Ingenol mebutate gel for actinic keratosis.

  The New England journal of medicine 20120315

• Ivacaftor, vismodegib, and ingenol mebutate.

  Journal of the American Pharmacists Association : JAPhA 20120101

• What's new in the treatment of actinic keratoses?

  Cutis 20110201

• Topical antineoplastic agents in the treatment of mucocutaneous diseases.

  Current problems in dermatology 20110101

• Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta.

  The Journal of biological chemistry 20100730

• The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.

  Cancer research 20100601

• Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

  European journal of haematology 20100301

• Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.

  Cancer research 20090515

• PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.

  The Australasian journal of dermatology 20090201

• Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

  British journal of cancer 20081202

• Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate.

  Journal of immunology (Baltimore, Md. : 1950) 20061201

• Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway.

  Cancer research 20061015

• HIV type 1 inhibition by protein kinase C modulatory compounds.

  AIDS research and human retroviruses 20060901

• PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.

  Blood 20050815

• Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells.

  Molecular cancer therapeutics 20041201

• Characterization of the interaction of ingenol 3-angelate with protein kinase C.

  Cancer research 20040501

• Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death.

  Cancer research 20040415